BIOGEN INC. (BIIB)

Biogen is a mid-sized biotechnology company with a history spanning three decades of drug discovery and development. The company is best known for its dominant franchise in multiple sclerosis — a neurological disease that Biogen essentially created a category to treat — and more recently for an Alzheimer’s drug that has reignited the company’s research ambitions. Biogen’s strategy is focused: rather than competing across dozens of therapeutic areas, the company concentrates on neurology, immunology, and rare genetic diseases where it can build expertise and maintain competitive advantages.

The core business — branded drugs sold to hospitals and pharmacies

Biogen makes money by discovering, developing, and selling pharmaceutical drugs. Patients with multiple sclerosis, spinal muscular atrophy, or other diseases take Biogen’s medicines, which they obtain through pharmacies or hospital infusion centers. Biogen sells directly to hospitals, pharmacy benefit managers, and, in some cases, to patients through specialty-pharmacy arrangements. Unlike a business that sells consumable products and repeats the cycle, Biogen’s revenue from a successful drug can be very long-lived: a patient might stay on the same therapy for decades, creating recurring revenue. However, this model faces disruption from patent expiration — once a drug’s patent ends, generic or biosimilar versions typically emerge and erode pricing power dramatically.

The company’s profit model depends entirely on drug prices. A neurology drug that treats a rare disease can command premium pricing because patients have few alternatives and health-insurance systems often have little choice but to pay. Biogen has historically been very aggressive in raising prices on established drugs, sometimes by double-digit percentages annually. This pricing power has funded research and development of new therapies, but it has also drawn public and regulatory scrutiny.

Multiple sclerosis — the franchise that built Biogen

Multiple sclerosis affects roughly 2.8 million people worldwide; Biogen pioneered injectable interferons that slow the disease and established itself as the dominant treatment company in the category. MS patients typically remain on therapy for life, which means recurring revenue from patients diagnosed decades ago. Biogen’s MS franchise — including drugs like Avonex and Tecfidera — has generated tens of billions in cumulative revenue and is still a significant profit driver.

The downside is patent expiration. Biogen’s older MS drugs have lost or are losing exclusivity, and the company has faced competition from newer, more convenient therapies developed by Roche and others. Biogen’s market share in MS has shrunk. The company is transitioning toward its newer MS drug, Vumerity, which has a longer patent life, but the transition is gradual and the near-term effect is margin compression.

Beyond MS — the bet on new categories

Biogen’s strategy to offset the MS franchise decline centers on spinal muscular atrophy and Alzheimer’s disease. Spinal muscular atrophy is a genetic disorder affecting children; Biogen’s drug Zolgensma is one of the most expensive medicines ever developed, priced at well over a million dollars per treatment. The market is tiny — only hundreds of patients diagnosed annually — but the revenue per patient is extraordinary. This is the essence of rare-disease strategy: identify a disease with no effective treatment, develop the only drug, and price it to capture most of the value.

The Alzheimer’s bet is larger. Biogen and its partner Eli Lilly co-developed Aducanumab (later Aduhelm), an intravenous monoclonal antibody aimed at clearing amyloid plaques in the brain. The drug achieved regulatory approval from the FDA, but with an unusual accelerated pathway that later drew scrutiny — evidence of efficacy was contested, and Medicare later declined to cover it widely. A newer variant, lecanemab, has shown clearer benefit in early-stage cognitive decline and has been approved and marketed. If lecanemab achieves adoption across the hundreds of millions of elderly people with mild cognitive impairment or early dementia, it could become a blockbuster, replacing some of the MS revenue loss. However, efficacy is modest — the drug slows decline but does not stop or reverse disease — and uptake depends on reimbursement and clinical adoption.

The research pipeline and capital allocation

Biogen invests heavily in research and development, typically spending 20–25% of revenue in this area. The company has a handful of drugs in mid-to-late-stage clinical trials and a broader pipeline of earlier-stage candidates. Success in drug development is probabilistic — only a small fraction of drugs that enter clinical trials ultimately reach patients — so Biogen must balance investment in its current revenue drivers with funding for next-generation therapies.

The company has also pursued acquisitions and partnerships to in-license drugs from smaller biotech companies, a common strategy to strengthen the pipeline. These deals can be expensive; a successful asset in mid-stage testing can cost hundreds of millions of dollars, and Biogen’s balance sheet and cash generation historically supported this approach. However, the company’s recent focus has shifted toward capital discipline and returning cash to shareholders through dividends and buybacks, rather than pursuing aggressive M&A.

The patent cliff and margin pressure

Biogen faces an acute patent-cliff scenario over the next five to ten years. As MS drugs lose exclusivity, gross margins will compress; the company will shift from charging premium prices to competing on price against generics and other branded alternatives. Staying profitable requires that newer drugs (lecanemab, spinal muscular atrophy, other pipeline candidates) achieve sufficient adoption to offset the MS decline. This is the central strategic tension in Biogen’s business: innovation must outpace obsolescence.

How to research Biogen

Investors should start with the 10-K filing (SEC CIK 0000875045), which breaks revenue down by drug and by geography, and discloses the company’s pipeline of drugs in development along with their stage and timeline. Track the near-term patent expirations and the anticipated launch dates for new drugs; a company with an empty launch calendar facing multiple patent cliffs is in deep trouble.

Study the clinical trial data on Alzheimer’s and other pipeline drugs. Efficacy and safety data determine whether drugs will be approved and, once approved, how widely they will be adopted. A trial that shows modest benefit may not be sufficient to convince neurologists to switch patients from older drugs.

Watch the gross margin trend. As older drugs lose exclusivity and newer ones ramp up, margins will shift. Monitor pricing actions on key drugs, particularly any price decreases or access restrictions (which signal eroding competitive position). Finally, pay attention to competition — other companies are developing MS therapies, Alzheimer’s drugs, and rare-disease treatments. Biogen’s competitive moat in MS has weakened; its success in future categories will depend on research productivity and clinical efficacy relative to rivals.